GeoVax Labs Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
GOVX
- Investments
-
1
- Share Price
-
$1.82
- (As of Friday Closing)
GeoVax Labs General Information
Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Contact Information
Website
www.geovax.comCorporate Office
- 1955 Lake Park Drive
- Suite 300
- Smyrna, GA 30080
- United States
Corporate Office
- 1955 Lake Park Drive
- Suite 300
- Smyrna, GA 30080
- United States
GeoVax Labs Timeline
GeoVax Labs Stock Performance
As of 20-Nov-2026, GeoVax Labs’s stock price is $1.82. Its current market cap is $985K with 544K shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.82 | $1.91 | $1.50 - $270.66 | $985K | 544K | 155K | -$35.78 |
GeoVax Labs Financials Summary
As of 30-Sep-2026, GeoVax Labs has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 555 | 2,396 | 14,713 | (3,051) |
| Revenue | 0 | 2,489 | 3,955 | 0 |
| EBITDA | (18,280) | (21,570) | (25,049) | (26,669) |
| Net Income | (18,263) | (21,465) | (24,992) | (25,967) |
| Total Assets | 3,424 | 6,342 | 8,156 | 9,283 |
| Total Debt | 250 | 843 | 0 | 0 |
GeoVax Labs Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GeoVax Labs Comparisons
Industry
Financing
Details
GeoVax Labs Competitors (30)
One of GeoVax Labs’s 30 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Arbutus Biopharma | Corporation | Warminster, PA | ||||
| Cytodyn | Formerly Angel backed | Vancouver, WA | ||||
| Verastem | Formerly VC-backed | Needham, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
GeoVax Labs Patents
GeoVax Labs Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026085259-A1 | Single-dose mva vaccines for protection against orthopoxvirus | Pending | 15-Oct-2024 | ||
| WO-2024206243-A1 | Pan-betacoronavirus vaccines and uses thereof | Inactive | 24-Mar-2023 | ||
| AU-2022215566-A1 | Viral constructs for use in enhancing t-cell priming during vaccination | Pending | 02-Feb-2021 | ||
| AU-2022215566-A9 | Viral constructs for use in enhancing t-cell priming during vaccination | Pending | 02-Feb-2021 | ||
| CA-3206004-A1 | Viral constructs for use in enhancing t-cell priming during vaccination | Pending | 02-Feb-2021 | C12N15/86 |
GeoVax Labs Signals
GeoVax Labs Acquisitions (1)
GeoVax Labs’s most recent deal was a Merger/Acquisition with Dauphin Technology. The deal was made on 28-Sep-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dauphin Technology | 28-Sep-2006 | Merger/Acquisition | Computers, Parts and Peripherals |
GeoVax Labs ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.81 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
GeoVax Labs FAQs
-
When was GeoVax Labs founded?
GeoVax Labs was founded in 2001.
-
Where is GeoVax Labs headquartered?
GeoVax Labs is headquartered in Smyrna, GA.
-
What is the size of GeoVax Labs?
GeoVax Labs has 19 total employees.
-
What industry is GeoVax Labs in?
GeoVax Labs’s primary industry is Drug Discovery.
-
Is GeoVax Labs a private or public company?
GeoVax Labs is a Public company.
-
What is GeoVax Labs’s stock symbol?
The ticker symbol for GeoVax Labs is GOVX.
-
What is the current stock price of GeoVax Labs?
As of 20-Nov-2026 the stock price of GeoVax Labs is $1.82.
-
What is the current market cap of GeoVax Labs?
The current market capitalization of GeoVax Labs is $985K.
-
Who are GeoVax Labs’s competitors?
Ayala Pharmaceuticals, Arbutus Biopharma, Cytodyn, Verastem, and Inovio Pharmaceuticals are some of the 30 competitors of GeoVax Labs.
-
What is GeoVax Labs’s annual earnings per share (EPS)?
GeoVax Labs’s EPS for 12 months was -$35.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process